4.2(top 10%)
impact factor
10.4K(top 2%)
papers
429.1K(top 1%)
citations
209(top 1%)
h-index
4.5(top 10%)
extended IF
13.0K
all documents
445.5K
doc citations
293(top 2%)
g-index

Top Articles

#TitleJournalYearCitations
1Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adultsAlimentary Pharmacology and Therapeutics20112,569
2Review article: the role of butyrate on colonic functionAlimentary Pharmacology and Therapeutics20082,048
3The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progressAlimentary Pharmacology and Therapeutics19971,186
4Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology and Therapeutics20021,068
5Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosisAlimentary Pharmacology and Therapeutics2009703
6Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitisAlimentary Pharmacology and Therapeutics1997700
7Review article: gastrointestinal features in COVID‐19 and the possibility of faecal transmissionAlimentary Pharmacology and Therapeutics2020679
8A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasisAlimentary Pharmacology and Therapeutics2005676
9Increasing prevalence of coeliac disease over timeAlimentary Pharmacology and Therapeutics2007662
10The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjectsAlimentary Pharmacology and Therapeutics2003654
11Review article: the global emergence ofHelicobacter pyloriantibiotic resistanceAlimentary Pharmacology and Therapeutics2016546
12Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's diseaseAlimentary Pharmacology and Therapeutics2006543
13Review article: prebiotics in the gastrointestinal tractAlimentary Pharmacology and Therapeutics2006536
14Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imagingAlimentary Pharmacology and Therapeutics2005522
15Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s diseaseAlimentary Pharmacology and Therapeutics2011513
16Review article: bifidobacteria as probiotic agents – physiological effects and clinical benefitsAlimentary Pharmacology and Therapeutics2005507
17Development of the GerdQ, a tool for the diagnosis and management of gastro‐oesophageal reflux disease in primary careAlimentary Pharmacology and Therapeutics2009497
18Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infectionAlimentary Pharmacology and Therapeutics2018497
19Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology and Therapeutics2011495
20Colorectal cancer prevention in ulcerative colitis: a case‐control studyAlimentary Pharmacology and Therapeutics2000492
21Chronic constipation: a survey of the patient perspectiveAlimentary Pharmacology and Therapeutics2007492
22Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitisAlimentary Pharmacology and Therapeutics1999485
23Review article: short chain fatty acids in health and diseaseAlimentary Pharmacology and Therapeutics1998478
24Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndromeAlimentary Pharmacology and Therapeutics2009467
25Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infectionAlimentary Pharmacology and Therapeutics2015467
26Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel diseaseAlimentary Pharmacology and Therapeutics2003466
27Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infectionAlimentary Pharmacology and Therapeutics2017455
28Review article: dietary fibre-microbiota interactionsAlimentary Pharmacology and Therapeutics2015430
29Review article: serotonin receptors and transporters — roles in normal and abnormal gastrointestinal motilityAlimentary Pharmacology and Therapeutics2004428
30Review article: yeast as probiotics –Saccharomyces boulardiiAlimentary Pharmacology and Therapeutics2007428
31Review article: lactose intolerance in clinical practice – myths and realitiesAlimentary Pharmacology and Therapeutics2008426
32Tegaserod, a 5‐HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipationAlimentary Pharmacology and Therapeutics2001425
33Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndromeAlimentary Pharmacology and Therapeutics2018423
34A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea‐predominant irritable bowel syndromeAlimentary Pharmacology and Therapeutics2003416
35Irritable bowel syndrome in the United States: prevalence, symptom patterns and impactAlimentary Pharmacology and Therapeutics2005413
36Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double‐blind placebo‐controlled trialAlimentary Pharmacology and Therapeutics1995413
37The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic reviewAlimentary Pharmacology and Therapeutics2002403
38Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitisAlimentary Pharmacology and Therapeutics2006403
39Systematic review: the global incidence and prevalence of peptic ulcer diseaseAlimentary Pharmacology and Therapeutics2009398
40Systematic review: impact of constipation on quality of life in adults and childrenAlimentary Pharmacology and Therapeutics2010392
41Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patientsAlimentary Pharmacology and Therapeutics2014389
42Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndromeAlimentary Pharmacology and Therapeutics2007387
43Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infectionAlimentary Pharmacology and Therapeutics2011377
44Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot studyAlimentary Pharmacology and Therapeutics2001370
45Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot studyAlimentary Pharmacology and Therapeutics2006368
46Review article: the epidemiology and prevention of gastric cancerAlimentary Pharmacology and Therapeutics2014368
47Natural history and epidemiology ofHelicobacter pyloriinfectionAlimentary Pharmacology and Therapeutics2002364
48Adipokines and cytokines in non‐alcoholic fatty liver diseaseAlimentary Pharmacology and Therapeutics2008364
49Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitisAlimentary Pharmacology and Therapeutics2014363
50Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazoleAlimentary Pharmacology and Therapeutics1999362